 SINGAPORE, March 03, 2021 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals Nasdaq: ASLN, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000 American Depositary Shares ADSs representing 75,000,000 ordinary shares at a price to the public of 4.00 per ADS. The gross proceeds from this offering are expected to be 60.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by ASLAN. The offering is expected to close on or about March 5, 2021, subject to customary closing conditions. In addition, ASLAN has granted the underwriters a 30-day option to purchase up to 2,250,000 additional ADSs at the public offering price, less the underwriting discounts and commissions. 